Neurocrine Bio. (NBIX) PT Raised to $131 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Neurocrine Bio. (NBIX) and TAK Collaboration Could Be Transformative - Canaccord Genuity
June 18, 2020 11:34 AM EDTCanaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $134.00 price target on Neurocrine Bio. (NASDAQ: NBIX), citing a major pact with Takeda Pharmaceutical Co Ltd. (NYSE: TAK) to develop seven neuropsychiatry-focused products. The deal helps bolster Neurocrine as a company not solely dependent on Ingrezza, as well as makes Neurocrine a key player in neuro-focused business development. These components all make NBIX more of a hunter than the... More
